ClinicalTrials.gg
Status unknownNCT04728984Updated Jan 28, 2021

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

A Phase 3 interventional study of Nalfurafine Hydrochloride and Nalfurafine Hydrochloride+Placebo in Uremic Pruritus, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.

Planned enrollment
3rd of 10
135 · median 99
Started
2020
the only one that year
Phase 3
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Shenyang Sunshine Pharmaceutical Co., LTD.

Among the 10 studies testing TRK 820 in Pruritus, this one is the 3rd largest by planned enrollment, is the only one that started in 2020, is one of 3 in phase 3, and was the 6th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About TRK 820

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing TRK 820 in Pruritus, or all of them as a file.
02

Study summary

This is a multisite study to evaluate the efficacy, safety and plasma concentration of Nalfurafine Hydrochloride orally disintegrating tablet in the treatment of refractory pruritus in maintenance hemodialysis patients, and to bridge the efficacy data from Japan

Read the detailed description

This clinical trial is a bridging study. when selecting the subjects, the most appropriate pruritus medication for the subjects was used first.Then, subjects with "existing treatment-resistant" pruritus will continue to receive basic pruritus treatment if the corresponding treatment is not sufficiently effective, and the experimental drug or placebo will be added to this treatment to evaluate the effectiveness.

03

Conditions studied

  • Uremic Pruritus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic renal failure patients who have been on stable dialysis for 3 months or more, receive regular hemodialysis 3 times a week, and expect no significant treatment changes or dramatic changes in their condition during the clinical trial;
  2. In the 1 year prior to signing the , patients who were treated with the following drugs A and/or B: (A) Systematic treatment (oral, injection, etc.) of "prescribed drugs for pruritus" (including antihistamines or antiallergic drugs) for more than 2 weeks consecutively; (B). Use of " prescribed drugs for pruritus" (ointments, etc.) or topical treatment of moisturizers prescribed by physicians;
  3. Patients who had received treatment in inclusion criteria (2) but did not respond;
  4. When signing the informed consent, the patient is older than 18 years old (including 18 years old), regardless of gender;
  5. During the observation period before administration (D8-14), the number of days for which the VAS values were measured at the time of getting up and going to bed should not be less than 5 days, and the average value of the larger VAS values in the morning and evening measurements should not be less than 50 mm;
  6. During the observation period before administration (D8-14), The number of days in which the larger VAS value measured in the morning and evening measurements (if there was a missing time in getting up or going to bed, the value which has been measured was selected) is not less than 20 mm, was not less than 5 days;
  7. During the observation period before administration (D8-14), the number of days in which the pruritus severity of Hsie-Kawashima's was evaluated at the time of getting up and at the time of going to bed was not less than 5 days, in which the maximum of the pruritus score was not less than 3 (moderate) in the morning and evening measurements was more than half.

Exclusion criteria

Exclusion Criteria:

  1. Malignant tumor patients;
  2. Patients with mental illness or mental retardation who cannot correctly understand the VAS score and describe their feelings;
  3. Patients with (ALT), aspartate aminotransferase (AST) or glutamine transferase (GGT) or total higher than twice the value (ULN) at the screening stage;
  4. Patients currently suffering from atopic dermatitis or chronic urticaria;
  5. Patients allergic to opioids;
  6. Patients with drug or alcohol dependence;
  7. Patients who had received light therapy for pruritus within 1 month prior to signing the ;
  8. Patients who have participated in a previous clinical study of Nalfurafine Hydrochloride and have taken Nalfurafine Hydrochloride, or who have participated in this clinical study and have been officially enrolled;
  9. Participated in other clinical studies (including research drugs and medical devices) within 1 month before signing the informed consent;
  10. Pregnant women, lactating women, women who have a positive pregnancy test or who do not agree to use during the study period;
  11. Patients who, as determined by the investigator, could not have their VAS score recorded by themselves for any reason;
  12. Patients whose comorbidities or previous medical history, as determined by the investigator, would affect the evaluation of this clinical study;
  13. After testing, antibody positive;
  14. Other patients judged by the investigator to be unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Nalfurafine Hydrochloride 5μg

    Oral administration after dinner, once daily for 14 consecutive days

    Drug: Nalfurafine Hydrochloride

  • Experimental
    Nalfurafine Hydrochloride 2.5μg

    Oral administration after dinner, once daily for 14 consecutive days

    Drug: Nalfurafine Hydrochloride+Placebo

  • Placebo comparator
    Placebo

    Oral administration after dinner, once daily for 14 consecutive days

    Drug: Placebo

Interventions

  • Nalfurafine Hydrochloride 2.5μg\*2 ; Oral administration after dinner, once daily for 14 consecutive days

  • DrugNalfurafine Hydrochloride+Placebo

    Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days

  • DrugPlacebo

    two placebo pills; Oral administration after dinner, once daily for 14 consecutive days

06

What researchers measure

Primary outcomes

  1. Variation in VAS of Nalfurafine Hydrochloride versus Placebo

    The Variation = the mean of the daily maximum VAS value during the observation period before administration(D8-14) - the mean of the daily maximum VAS value during the administration period (D25-31). Only the days on which the VAS values were recorded during the day and night were evaluated.

    Time frame: up to 38(+1) days

Secondary outcomes

  1. Variation in pruritus scores based on the Hsie-Kawashima pruritus severity assessment method

    Pruritus scores were assessed during the observation period before administration(D8-14) and administration period (D25-31), and only the days when pruritus scores were recorded during the day and night were evaluated.

    Time frame: up to 38(+1) days

  2. Variation in nocturnal pruritus scores based on the Hsie-Kawashima pruritus severity assessment method (improvement of pruritus-induced sleep disorders).

    After calculating the mean values of nocturnal pruritus scores during the observation period before administration(D8-14) and administration period (D25-31), the variation was calculated.

    Time frame: up to 38(+1) days

  3. Improvement degree of VAS

    The average VAS value of the observation period before administration (D8-14) and the average VAS value of the administration period (D25-31) were calculated, and the improvement degree was determined as very effective, effective and ineffective according to the variation of the average VAS value.

    Time frame: up to 38(+1) days

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Medical College of Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Chen Jianghua, Master · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Jun 2021, 9 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 9 months is below that.

Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2021
First posted
Jan 28, 2021
StartActual
Sep 7, 2020
Primary completionEst.
Jun 30, 2021
CompletionEst.
Oct 31, 2021
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04728984
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Sep 7, 2020
Primary completion
Jun 30, 2021 (estimated)
Completion
Oct 31, 2021 (estimated)
Last update
Jan 28, 2021

Study contacts

Chen Jianghua, Master
Contact
chenjianghua@zju.edu.cn
0571-87236992

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK 820

Start the discussion